Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial. MRC Childhood Leukaemia Working Party.

2.50
Hdl Handle:
http://hdl.handle.net/10541/86371
Title:
Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial. MRC Childhood Leukaemia Working Party.
Authors:
Harrison, G; Richards, S; Lawson, S; Darbyshire, P; Pinkerton, R; Stevens, R; Oakhill, A; Eden, Tim O B
Abstract:
BACKGROUND: Although reinduction rates are good for children with relapsed acute lymphoblastic leukaemia there is no consensus on whether bone marrow transplantation (BMT) is the most effective treatment to prolong second remission. PATIENTS AND METHODS: Analyses comparing the outcome of related donor allogeneic BMT (related allograft) with chemotherapy are unreliable because of selection biases. To avoid these biases, the MRC UKALL R1 trial was analysed by HLA-matched donor availability. RESULTS: No significant difference in outcome was found between the donor and no donor groups. The donor group had a non-significant eight-year event-free survival (EFS) advantage of 8%, (95% confidence interval -9%-24%) over the no donor group. Patients with a first remission less than two years appeared to benefit most from having a donor, although the effect was only marginally significantly different from patients with longer first remission. Analysis by treatment received gave similar results, with BMT patients having a 5% (P = 0.8) eight-year EFS advantage over patients who received chemotherapy. CONCLUSIONS: Related allograft was not found to be significantly better than chemotherapy, but there was the possibility of a moderate EFS benefit with related allograft. especially in patients with a short first remission.
Affiliation:
Clinical Trial Service Unit, Radcliffe Infirmary, Oxford, UK.
Citation:
Comparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial. MRC Childhood Leukaemia Working Party. 2000, 11 (8):999-1006 Ann. Oncol.
Journal:
Annals of Oncology
Issue Date:
Aug-2000
URI:
http://hdl.handle.net/10541/86371
PubMed ID:
11038037
Type:
Article
Language:
en
ISSN:
0923-7534
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorHarrison, Gen
dc.contributor.authorRichards, Sen
dc.contributor.authorLawson, Sen
dc.contributor.authorDarbyshire, Pen
dc.contributor.authorPinkerton, Ren
dc.contributor.authorStevens, Ren
dc.contributor.authorOakhill, Aen
dc.contributor.authorEden, Tim O Ben
dc.date.accessioned2009-11-18T11:41:34Z-
dc.date.available2009-11-18T11:41:34Z-
dc.date.issued2000-08-
dc.identifier.citationComparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial. MRC Childhood Leukaemia Working Party. 2000, 11 (8):999-1006 Ann. Oncol.en
dc.identifier.issn0923-7534-
dc.identifier.pmid11038037-
dc.identifier.urihttp://hdl.handle.net/10541/86371-
dc.description.abstractBACKGROUND: Although reinduction rates are good for children with relapsed acute lymphoblastic leukaemia there is no consensus on whether bone marrow transplantation (BMT) is the most effective treatment to prolong second remission. PATIENTS AND METHODS: Analyses comparing the outcome of related donor allogeneic BMT (related allograft) with chemotherapy are unreliable because of selection biases. To avoid these biases, the MRC UKALL R1 trial was analysed by HLA-matched donor availability. RESULTS: No significant difference in outcome was found between the donor and no donor groups. The donor group had a non-significant eight-year event-free survival (EFS) advantage of 8%, (95% confidence interval -9%-24%) over the no donor group. Patients with a first remission less than two years appeared to benefit most from having a donor, although the effect was only marginally significantly different from patients with longer first remission. Analysis by treatment received gave similar results, with BMT patients having a 5% (P = 0.8) eight-year EFS advantage over patients who received chemotherapy. CONCLUSIONS: Related allograft was not found to be significantly better than chemotherapy, but there was the possibility of a moderate EFS benefit with related allograft. especially in patients with a short first remission.en
dc.language.isoenen
dc.subjectPrecursor Cell Lymphoblastic Leukaemia-Lymphomaen
dc.subject.meshAdolescent-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshBias (Epidemiology)-
dc.subject.meshBone Marrow Transplantation-
dc.subject.meshChild-
dc.subject.meshChild, Preschool-
dc.subject.meshDisease-Free Survival-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshInfant-
dc.subject.meshInfant, Newborn-
dc.subject.meshMale-
dc.subject.meshPrecursor Cell Lymphoblastic Leukemia-Lymphoma-
dc.subject.meshRecurrence-
dc.subject.meshTransplantation, Homologous-
dc.titleComparison of allogeneic transplant versus chemotherapy for relapsed childhood acute lymphoblastic leukaemia in the MRC UKALL R1 trial. MRC Childhood Leukaemia Working Party.en
dc.typeArticleen
dc.contributor.departmentClinical Trial Service Unit, Radcliffe Infirmary, Oxford, UK.en
dc.identifier.journalAnnals of Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.